UNSPSC 51172700: Combination antispasmodics

This classification denotes combination drugs that inhibit the actions of the parasympathetic nervous system, sometimes also called spasmolytics, or drugs which inhibit spasms, hence the term ANTISPASMODICS. Typical combination antispasmodic constituents are atropine, belladonna, butabarbital, hyoscyamine, hyoscyamus, and methenamine.

UNSPSC 51172700 Combination antispasmodics is a Class code that encompasses pharmaceutical products and related specimen collection, testing, and pharmacy benefit administration services procured by state and local health and criminal justice agencies. Recent state and local solicitations reveal that buying under this code extends well beyond the nominal product category to include drug testing services, pharmacy benefit management program design, and multi-source generic pharmaceutical procurement. The issuing bodies include county criminal justice departments, state health and human services agencies, and multi-state cooperative purchasing alliances operating on behalf of state and local government members. Collin County Community Supervision and Corrections Department (Texas) is actively procuring specimen collection and drug testing services under RFP 2026-327, with proposals due July 23, 2026, for an estimated contract value of $600,000 over two years with optional renewals to five years total, encompassing immunoassay screening and confirmation testing at two collection sites in the Dallas-Fort Worth area. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative pharmaceutical distribution models.

Recent procurement activity under this code concentrates in Texas and the Upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to participating state and local government facilities across multiple states including Oregon. This MMCAP contract, effective July 1, 2026, requires manufacturers to supply products with specific National Drug Codes and maintain cGMP and Drug Supply Chain Security Act compliance, with pricing weighted at 75 percent of the evaluation score and contract terms of two years for new vendors with optional extensions through June 30, 2028. The three opportunities span different procurement structures—transactional RFP (Collin County), exploratory market research (Texas HHS), and multi-award cooperative purchasing (MMCAP)—reflecting varied state and local approaches to pharmaceutical and drug-testing product sourcing.